TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03063632

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon Gamma-1b
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon Gamma-1b
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04300777

Intervention type: DEVICE
Intervention: SeaSpine Non-Cervical Pedicle Screw Systems
Description: Any patient treated with a SeaSpine Non-Cervical Pedicle Screw System
Study: NCT02688127

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: tranexamic acid or placebo are given before cesarean section in patient with placenta previa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: tranexamic acid or placebo are given before cesarean section in patient with placenta previa
Study: NCT05448859

Intervention type: PROCEDURE
Intervention: intracytoplasmic sperm injection
Description: injection of sperm into an oocyte in assisted reproductive technology

Intervention type: PROCEDURE
Intervention: intracytoplasmic sperm injection
Description: injection of sperm into an oocyte in assisted reproductive technology

Intervention type: PROCEDURE
Intervention: intracytoplasmic sperm injection
Description: injection of sperm into an oocyte in assisted reproductive technology

Intervention type: PROCEDURE
Intervention: intracytoplasmic sperm injection
Description: injection of sperm into an oocyte in assisted reproductive technology

Intervention type: PROCEDURE
Intervention: intracytoplasmic sperm injection
Description: injection of sperm into an oocyte in assisted reproductive technology
Study: NCT01181856

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA 85A
Description: Single injection of 1 x 108 pfu MVA85A

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA 85A
Description: Single injection of 1 x 108 pfu MVA85A
Study: NCT02657993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: The hypnosis intervention involves three parts. First, participants will receive three, face-to-face hypnosis sessions delivered by doctoral-level psychology professionals. The sessions are based on materials developed by experienced psychologists in the Integrative Behavioral Medicine Program at the Icahn School of Medicine at Mount Sinai. Second, participants will be taught how to use hypnosis themselves (self-hypnosis) to help manage their pain. Third, participants will receive a hypnosis recording to listen to in-between sessions and throughout the course of the study. At home hypnosis practice will be recommended.~Participants will be asked to complete questionnaires over a period of 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: The attention control intervention involves three face-to-face meetings with a doctoral-level psychology professional. During these sessions, participants will be asked to discuss with the interventionist their experience of taking aromatase inhibitors and associated musculoskeletal pain. The interventionist will not lead the patient in imagery, relaxation, evaluation of thought processes, or even simple discussion. Rather interventionists will allow the patient to direct the flow of the conversation and will provide support and empathy. Interventionist contact time in AC sessions will be identical to that in the hypnosis group. Overall, the attention control intervention will control for professional attention.~Participants will be asked to complete questionnaires over a period of 12 months.
Study: NCT04083339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-001
Description: AT-001 will be administered as 3 capsules twice daily, before breakfast and before dinner.~At present AT001 is the sole name for the active substance. No INN/genetic name is available to date

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-001
Description: AT-001 will be administered as 3 capsules twice daily, before breakfast and before dinner.~At present AT001 is the sole name for the active substance. No INN/genetic name is available to date

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as 3 capsules twice daily, before breakfast and before dinner
Study: NCT01916564

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Split-dose
Description: 2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Same-morning whole-dose
Description: 2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy
Study: NCT01665053

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PROMUS Element Plus
Description: A drug eluting coronary stent system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNERGY
Description: A drug eluting coronary stent system
Study: NCT00548990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cardiovascular exercise training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: flexibility/balance control
Study: NCT00564174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin and low dose aspirin
Description: Fragmin 5000 IU/day by subcutaneous injection started at time of randomization and continued until 35 weeks gestation or delivery and low dose aspirin 81 mg/day started pre-conception and continued until 35 weeks gestation or delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose aspirin
Description: 81 mg enteric coated started pre-pregnancy and discontinued at 35 weeks or delivery
Study: NCT04582227

Intervention type: DEVICE
Intervention: Ambu aura-i LMA
Description: The ETT or the LMA will be inserted with the patient's head position is aided either by pins or head rest, and either the head will be in neutral position or tilted as long as the airway device is successfully placed.
Study: NCT03212105

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Brochure
Description: The educational pamphlet will contain information about pain and stress, which patients will be able to read within 60 seconds.
Study: NCT03856879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive E-consult
Description: E-consult recommendations and orders will be developed by a panel of pulmonologists and will address a range of care elements for patients with COPD.
Study: NCT00560183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q8003 (morphine sulfate and oxycodone hydrochloride)
Description: Capsules, four different mg dosage strengths

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study: NCT01847183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Click City®: Alcohol
Description: A school based program, Click City®: Alcohol consists of 12 effective components delivered in 7th grade and a booster of 5 effective components delivered in 8th grade.
Study: NCT00303992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT01092520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Day 1 - 5mg/kg/dose per os at bedtime then 5mg/kg/dose PO b.i.d x 1 day (Day 2) then on Day 3, 5mg/kg/dose PO t.i.d . x 19 days; after 7 days, if not at maximal effect may increase over 3 days to 10mg/kg/dose (Day 8: 5 mg/kg/dose q.am and midday, Day 9: 10mg/kg/dose b.i.d. + 5mg/kg/dose midday, Day 10: 10mg/kg/dose t.i.d.) Doses may be reduced if patient experiences intolerable side effects.
Study: NCT02139345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TC-A PS Total Knee Replacement System
Description: Subject will be implanted with the TC-A PS Total Knee Replacement System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TC-PLUS Solution PS Total Knee Replacement System
Description: Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System
Study: NCT03970447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Dosage Form: Capsule for oral administration Strengths: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Dosage Form: Capsule for oral administration Strength: 5 mg, 10 mg, 40 mg, and 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Dosage Form: Tablet for oral administration Strength: 40 mg Standard Regimen: 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: 60 Gy
Study: NCT02992041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 Injections
Description: IV infusion of 900 or 1100 mg of VVZ-149

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion of 0 mg of VVZ-149
Study: NCT01357317

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet counseling
Description: If serum phosphorus level exceeds 4.6 mg/dl in the lanthanum carbonate arm in spite of consecutive up-titration of the medical dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet counseling
Description: If serum phosphorus level exceeds 4.6 mg/dl in spite of consecutive up-titration of the medication dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phosphorus binder
Description: If serum phosphorus level exceeds 4.6 mg/dl after 3 months of concerted efforts, the patient will be considered a treatment failure and treatment with a phosphorus binder of the treating physician's choice will be allowed.
Study: NCT05989360

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung Clearance Index
Description: Normative values in healthy children from ethnic backgrounds
Study: NCT00006081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bryostatin-1
Description: 40 mcg/m2 one-hour infusion 24 hours after each dose of paclitaxel (i.e., day 2, 9, 16).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol)
Description: 80 mg/m\^2 one-hour infusion weekly x 3 every 4 weeks
Study: NCT02197728

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy
Study: NCT01162590

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix ™
Description: Oral, single dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, single dose
Study: NCT02277314

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Manual Small Incision Cataract Surgery
Description: This cost-effective solution for removing cataracts, also known as Manual Small Incision Cataract Surgery (MSICS), is a positive alternative when Phaco is not an option due to costs. The procedure takes approximately 30 minutes and involves a mid-size incision and an intraocular lens (IOL), or artificial lens, replacing the natural lens. Following the procedure, patients may need glasses, and most will need bifocals, but overall vision will be significantly improved.
Study: NCT01133392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro A
Description: 20 units (U) subcutaneously (SC).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro B
Description: 20 U subcutaneously (SC).
Study: NCT00686374

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Participants who enrolled into the study from blinded therapy in Study M06-806 received open-label (OL) therapy at a dose dependent on their body weight. Participants weighing ≥ 40 kg received 40 mg of adalimumab every other week (eow), and those who weighed \< 40 kg received 20 mg of adalimumab eow. Starting at Week 8, participants who had a disease flare may have been switched to every week (ew) treatment at the same dose of adalimumab received while on eow treatment. Participants who enrolled from OL therapy in Study M06-806 continued to receive the same dose they were receiving (i.e., 40 mg ew or 20 mg ew) at the Week 52 visit of Study M06-806. Adalimumab dose could have been decreased to the next lower treatment level for those with body weight changes. Participants who responded to treatment may have also had their dosage frequency decreased from ew to eow dosing, as well as a decrease in dosage.
Study: NCT03425591

Intervention type: DRUG
Intervention: Ibrutinib
Description: Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib in routine clinical practice settings will be observed for 5 years.

Intervention type: DRUG
Intervention: Ibrutinib
Description: Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib in routine clinical practice settings will be observed for 5 years.
Study: NCT03549130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breathe Right Tan (small/medium) nasal strips
Description: Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (Breathe Right Tan), small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal strip
Description: Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips, small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
Study: NCT02452060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.4mg/kg infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 0.4mg/kg infusion
Study: NCT01858246

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bonebridge
Study: NCT03776357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VERA clinic
Description: A software system used with the Microsoft Kinect intended to support the physical rehabilitation of adults in the clinic and at home.
Study: NCT01648868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (rTMS)
Description: Excitatory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in patients with autism.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (rTMS)
Description: Inhibitory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in healthy controls
Study: NCT01199627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A
Description: Group A: 1st dose 15mg/kg of TXA (tranexamic acid) in 100ml saline 0.9% after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B
Description: Group B: 1st dose: 10mg/kg of TXA(tranexamic acid) in 100ml 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes of 10mg/kg of TXA in 100ml saline 0.9% at three hours after the first administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C
Description: Group C: 1st dose: intravenous infusion over 10 minutes in 100ml of 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration.
Study: NCT02706431

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Study: NCT04903639

Intervention type: DIAGNOSTIC_TEST
Intervention: sleep study
Description: The polysomnography consists of electroencephalogram (EEG), electrooculogram (EOG), electrocardiogram (ECG), electromyogram (EMG), pulse oximetry, thoracic and abdominal straps, body posture sensor, nasal thermistor and nasal cannula to assess respiratory flow and pressure and bipolar channel limb movements (tibialis anterior). Electrodes and sensors were attached to patients by sleep physiologist. Data collection was obtained following signal perception by preprocessed computer (DOMINO Software, ver. 2.6.0; SOMNO Medics GmbH).
Study: NCT01858246

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Anchored Hearing Aid
Study: NCT01712412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-9179

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03307512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro (Humalog U-100)
Description: Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection
Study: NCT02561312

Intervention type: OTHER
Intervention: Rapid manual partial exchange transfusion
Description: The first four participants will receive peripheral red blood cells via rapid manual partial exchange transfusions every month for 6 months. There is a pre-study washout for 3 months then there is a 3 month test period (data collection) before the participant is transferred to ST treatment.

Intervention type: OTHER
Intervention: Simple Transfusion
Description: The second group of four participants will receive peripheral red blood cells via simple transfusion every month for 6 months. There is a pre-study washout period for 3 months then there is a 3 month test period (data collection) before the participant is transferred to RMPET treatment.
Study: NCT02892669

Intervention type: OTHER
Intervention: non interventional study
Description: non interventional study
Study: NCT03472430

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: The TENS machine used in the study will be the Endomed 482 that delivers biphasic pulsed currents using pulse duration of 400 µs and pulse frequencies between 80-100 pulses.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS machine with electrodes not emitting any impulses.
Description: TENS machine with electrodes not emitting any impulses.
Study: NCT00792051

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated influenza vaccine
Description: 0.5ml intramuscular single dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.5ml intramuscular, one dose
Study: NCT01330823

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-Carnitine
Description: L-Carnitine, 4g/day, orally (Juice)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tartaric acid same dose like L-Carnitine as placebo
Study: NCT03799640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Yoga
Description: Yoga using standard poses and linear movements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Yoga
Description: Yoga using standard poses and linear movements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-directional Yoga
Description: The multidirectional yoga training program will use both simple and complex movement sequences (asana or postures) that include a cognitive component. For example, participants will be taught a movement sequence that includes 16-20 yoga postures that increase in difficulty as the training progresses.
Study: NCT03970447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxalisib
Description: Dosage Form: Tablet for oral administration Strength: 15 mg Standard Regimen: 45 mg orally (PO) every day for 28 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 28 days for all subsequent cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-083
Description: Dosage Form: Infusion for intravenous administration Strength: 40 mg per vial Standard Regimen: 30 mg/m2 on Day 1, 2 and 3 of 21-day cycle. The drug is available in powder form. It is reconstituted with 5 mL of 0.9% Sodium Chloride for Injection, USP. This will produce a solution of 40 mg VAL-083 in 5 mL. The required volume of reconstituted VAL-083 for the patient is then calculated at the rate of 30 mg/m2. The corresponding volume is further diluted into 250 mL of 0.9% Sodium Chloride for Injection, USP, prior to intravenous administration.
Study: NCT03799640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-directional Yoga
Description: The multidirectional yoga training program will use both simple and complex movement sequences (asana or postures) that include a cognitive component. For example, participants will be taught a movement sequence that includes 16-20 yoga postures that increase in difficulty as the training progresses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Control
Description: Lectures on health and fitness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Control
Description: Lectures on health and fitness
Study: NCT05373732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: meditation
Description: meditation practice 20 minutes twice a day at home and attending classes at the clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education control
Description: didactic based classes in CVD risk factor reduction and prevention